AtoOxy Predicted Responders for Obstructive Sleep Apnea (OSA)

Phase-Based Progress Estimates
Brigham and Women's Hospital, Boston, MA
Obstructive Sleep Apnea (OSA)+3 More
Oxybutynin - Drug
All Sexes
What conditions do you have?

Study Summary

Atomoxetine-plus-oxybutynin therapy (AtoOxy) has been shown to substantially reduce obstructive sleep apnea severity (OSA) in about half of patients. Here, the investigators study which patients respond meaningfully to therapy using pathophysiological traits measured at baseline sleep studies.

Eligible Conditions

  • Obstructive Sleep Apnea (OSA)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 3 days

3 days
Apnea-hypopnea index (AHI)
Arousal Index
Hypoxic Burden

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

AtoOxy Predicted Responders
1 of 2
AtoOxy Predicted Nonresponders
1 of 2
Experimental Treatment

22 Total Participants · 2 Treatment Groups

Primary Treatment: AtoOxy Predicted Responders · No Placebo Group · Phase 1 & 2

AtoOxy Predicted RespondersExperimental Group · 2 Interventions: Oxybutynin, Atomoxetine · Intervention Types: Drug, Drug
AtoOxy Predicted NonrespondersExperimental Group · 2 Interventions: Oxybutynin, Atomoxetine · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 days

Trial Background

Prof. Scott Aaron Sands, Assistant Professor of Medicine
Principal Investigator
Brigham and Women's Hospital
Closest Location: Brigham and Women's Hospital · Boston, MA
Photo of Boston  1Photo of Boston  2Photo of Boston  3
2008First Recorded Clinical Trial
14 TrialsResearching Obstructive Sleep Apnea (OSA)
1041 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
A diagnosis of OSA must be excluded before performing a routine diagnostic sleep study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.